In this special episode of Healthcare Unfiltered, Dr. Tanios Bekaii-Saab, of the Mayo Clinic, joins Dr. Chadi Nabhan to discuss the most groundbreaking studies unveiled at the 2024 ASCO GI Symposium, including an examination of the crucial, previously reported data from IMbrave050 and EMERALD-1.
Liver Cancer
Rising HCC mortality rates in the US highlight stark disparities across age, sex, race, and liver disease etiologies.
Kaplan-Meier curves showed that patients with high TBS had significantly decreased OS and increased recurrence rates.
A recent analysis reviewed patient-level data to identify the relationship between pathological response and relapse.
Repeated use of TACE can impair liver function and stimulate tumor angiogenesis.
Dr. Richard Finn provides an overview of the key studies in liver cancer from ESMO 2024.
HIMALAYA found tremelimumab plus durvalumab to significantly improve overall survival over sorafenib alone.
FDA approval comes after the IMscin001 trial, an open-label, multi-center, international analysis of adult patients.
A study compared the outcomes of patients with HCC who underwent upfront surgical resection versus neoadjuvant immunotherapy.
Dr. Amit Mahipal discusses a recent study on atezolizumab plus bevacizumab as a first-line treatment for HCC.
Amezalpat is a PPAR⍺ antagonist that modulates immune suppressive cells and angiogenesis in the tumor microenvironment.
Advertisement
Featured Podcast
Advertisement
Expert Interviews on GI Oncology
Advertisement
Section Editor
Richard S. Finn, MDProfessor of Medicine, Geffen School of Medicine | Jonsson Comprehensive Cancer Center | UCLA
Advertisement
Latest GI Oncology News
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.